Form 4: Emerald Bioventures Converts Galera Therapeutics Preferred

Emerald Bioventures, LLC converted 20,813.8186 shares of Series B Preferred Stock into 20,813,818 shares of Galera Therapeutics common stock.

Summary

• Emerald Bioventures, LLC and Timothy Opler reported the conversion of 20,813.8186 shares of Series B Non-Voting Convertible Preferred Stock into 20,813,818 shares of common stock.
• The conversion occurred on May 15, 2026, at a ratio of 1,000 shares of common stock per share of Series B Preferred Stock.
• Following the transaction, Emerald Bioventures holds 61,029,978 shares of common stock.
• The issuer will pay cash in lieu of any fractional shares resulting from the conversion.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event reflecting a change in the capital structure rather than a fundamental shift in company performance.

Positives

• Simplification of the capital structure by eliminating the Series B Preferred Stock class.

Negatives

• Increased dilution for existing common shareholders due to the issuance of over 20.8 million new common shares.

Risks

• Significant concentration of ownership by a single entity, Emerald Bioventures, which may influence corporate decision-making.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations, focusing solely on the change in beneficial ownership.

Management Comments

• The conversion was executed pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock.

Industry Context

StockSavvy.ai notes that large-scale conversions of preferred stock to common equity are common in biotech firms to clean up balance sheets, though they often signal a transition in investor strategy or a move toward simplifying the cap table for potential future financing or M&A activity.

Comparison to Industry Standards

• The conversion ratio of 1,000:1 is consistent with standard terms for private placement preferred securities in the biotechnology sector.
• The use of cash in lieu of fractional shares is a standard administrative practice in equity conversions.

Stakeholder Impact

• Existing shareholders face dilution from the issuance of 20.8 million new common shares.
• Emerald Bioventures increases its direct voting power and influence over the company.

Next Steps

• Payment of cash for fractional shares to the reporting person.

Key Dates

Keywords

Galera Therapeutics, GRTX, Emerald Bioventures, SEC Form 4, Preferred Stock Conversion, Insider Ownership